About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
Press ReleaseCardiawave announces positive 6-month data from its Valvosoft Pivotal Study, presented at TCT Conference ! Oct 29, 2024 READ MORE
About UsArticle Le Figaro: “Les immenses promesses cliniques des ultrasons thérapeutiques” Oct 15, 2024 READ MORE
EventsPr Hélène Eltchaninoff presenting Cardiawave’s latest clinical studies at TCT 2024 in Washington ! Oct 7, 2024 READ MORE
EventsJournée Mondiale du Coeur: Pr Damien Metz considère la technologie Valvosoft® comme un complément potentiel aux moyens thérapeutiques existants Sep 30, 2024 READ MORE
EventsJournée Mondiale du Coeur: Pr Hélène Eltchaninoff soutient les nouvelles solutions thérapeutiques telles que Valvosoft® pour la prise charge de la sténose aortique Sep 30, 2024 READ MORE
EventsClara Magnier, PhD student, presenting at the ISTU 2024 conference in Taipei (Taiwan) ! Sep 19, 2024 READ MORE
EventsCardiawave’s latest clinical studies results presented by Dr Marleen Van Wely and Prof. Emmanuel Messas at ESC Congress 2024 ! Aug 29, 2024 READ MORE
About Us 🔊 New Interview – Inside Cardiawave’s Journey with the EIC Scaling Club🎙️ Cardiawave’s presentation at LSI 2025 Jan 13, 2026 HeleneCardiawave 0
Press Release VALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 HeleneCardiawave 0
Press Release VALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 HeleneCardiawave 0
Events 📢 Cardiawave’s Valvosoft® to be presented at PCR London Valves 2025! Nov 6, 2025 HeleneCardiawave 0
Press Release Cardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 HeleneCardiawave 0
